About the company
GlycoTherapeutics is a drug development startup committed to overcome the efficacy limitations of current cancer immunotherapies. Less than 50% of individuals with cancer receiving immunotherapy obtain a durable response, which is partly due to glycobiology processes that suppress the immune system. Based on over a decade of research, GlycoTherapeutics’ proprietary solution targets these processes by disrupting the interaction of glycans (sugars) that are responsible for immune evasion to maximize the potential of immunotherapy. The company was established in 2022 as a spin-off from Radboud University, Nijmegen in the Netherlands and has raised >€1.5 million in non-dilutive funding.
Founding team
Events & News
Meet us at these events:
- BIO-Europe Spring, 18–20 March 2024 in Barcelona, Spain
- Global Investor Forum, 27 March 2024 in Rotterdam, the Netherlands
- Innovation for Health, 28 March 2024 in Rotterdam, the Netherlands
- Immuno 2024, 25–26 April 2024 in London, UK
- Bio€quity Europe, 12–14 May 2024 in San Sebastián, Spain
- SialoGlyco, 4–7 June 2024 in Lille, France
Other news:
Contact us
- Venture capitalists: GlycoTherapeutics is connecting with life science venture capitalists to join our mission
- Collaborators: We like to connect with more academic collaborators for preclinical validation of our technologies in relevant cancer models